Charles Lynde

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, Martin M. Okun, David Williams et al. · New England Journal of Medicine · 2016 · 741 citations

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 553 citations · Full text

A Comprehensive Approach to the Recognition, Diagnosis, and Severity-Based Treatment of Focal Hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee

Nowell Solish, Vince Bertucci, Alain Dansereau et al. · Dermatologic Surgery · 2007 · 412 citations

Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial

Thomas Ruzicka, Charles Lynde, Gregor B. E. Jemec et al. · British Journal of Dermatology · 2008 · 399 citations

Severe Che Refractory, Ophthalmology, Atopic Dermatitis +10

Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: A multicenter Canadian survey of 15,000 patients

Aditya K. Gupta, Hem C. Jain, Charles Lynde et al. · Journal of the American Academy of Dermatology · 2000 · 381 citations

Physicians ’ Offices, Clinical Epidemiology, Clinical Mycology +5